Abstract: This application provides methods and compositions related to constructing nucleic acid hydrogels (e.g., RNA hydrogels) having repetitive monomer units, each monomer unit includes one or more G-quadruplex sequences. These G-quadruplex sequences cross-link the nucleic acid concatemer such that it self-assembles into a hydrogel under appropriate conditions. In some embodiments, each monomeric unit of the nucleic acid concatemer comprises a coding sequence for polypeptide of interest; and the nucleic acid hydrogel formed by the nucleic acid concatemer can be used for expressing the polypeptide in high quantities. In some embodiments, at least two RNA concatemers comprising G-quadruplex sequences are produced, one further comprising a spacer and the other further comprising a sequence encoding a polypeptide of interest. These two RNA concatemers are combined and self assembled to form a single, wideband RNA hydrogel.

Abstract: The present invention relates to: a lyophilized preparation of a pathogen cell wall skeleton, the preparation containing the pathogen cell wall skeleton as an active ingredient; various live-pathogen-mimetic nanoparticles produced by using the lyophilized preparation and antagonists of toll-like receptor 7 or 8 which can induce the efficacy of the live pathogen; a use thereof; and a production method thereof.

Abstract: Ingestible devices with a relatively large payload volume or sample volume, as well as related components, systems and methods, are disclosed.

Abstract: An ingestible device is disclosed which can produce spectral data of one or more analytes, as well as associated methods for characterizing the gastrointestinal tract of a subject which contains such analytes. Related kits and systems are also disclosed.

Abstract: Compositions and methods, systems, and kits for detecting and quantifying variations in numbers of molecules, particularly variations in gene dosage, e.g., due to gene duplication, or to variations from the normal euploid complement of chromosomes, e.g., trisomy of one or more chromosomes that are normally found in diploid pairs, without digital sequencing.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a SMAD7 inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Abstract: An ingestible device, includes a storage reservoir configured to store a dispensable substance and a pressurized chamber configured so that, when a restraining force is removed from the pressurized chamber, the dispensable substance exits the ingestible device via openings in the ingestible device.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor.

Abstract: Methods and nucleic acid molecules for detecting chromosomal abnormalities such as aneuploidy. Methods for selecting nucleic acid molecules for use in the methods of the disclosure.

Abstract: Various embodiments are described herein for a device, system, and method for identifying a location of an ingestible device within a gastrointestinal tract of a body. In some embodiments, the ingestible device includes a sensing unit with an axial optical sensing sub-unit located proximal to at least one end of the device, and a radial optical sensing sub-unit located proximal to a radial wall of the device, and may autonomously identify a location within the gastrointestinal tract. In some embodiments, the ingestible device includes optical illumination sources and detectors that operate at a plurality of different wavelengths, and may discern regions of a gastrointestinal tract by using the reflection properties of organ tissue and occasional particulates. In some embodiments, the ingestible device may sample fluid or release medicament based on a detected device location.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor.

Abstract: The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

Abstract: Sampling systems that include an absorbent material a preservative, such as an analyte preservative, as well as related materials and methods, are disclosed.

Abstract: Methods and nucleic acid molecules for detecting chromosomal abnormalities such as aneuploidy. Methods for selecting nucleic acid molecules for use in the methods of the disclosure.

Abstract: Various embodiments are described herein for a device and method for an ingestible medical device with a rotatable element. In some described embodiments, the ingestible medical device includes a storage sub-unit with multiple chambers each having an opening for collecting or dispensing substances from the GI tract. The device further comprises a chamber enclosure with an access port. One of the chamber enclosure and the storage sub-unit are rotatable to allow for aligning the access port with a chamber opening. The ingestible medical device includes a sensor for positioning the access port of the chamber enclosure or the storage sub-unit as one of these elements rotates.

Abstract: A drug delivery device (50) is provided comprising a drug reservoir (10) and a piston (11). The drug reservoir (10) is provided for comprising a drug and comprises a flexible wall (22) and a dispensing hole (15) for dispensing the drug into an environment of the drug delivery device (50). The piston (11) is provide for pressing against the flexible wall (22) to compress the drug reservoir (10) for pushing an amount of the drug through the dispensing hole (15). An adhesion interface (51) between a surface of the piston (11) and the flexible wall (22) prevents sliding between the surface of the piston (11) and the flexible wall (22).

Abstract: The invention relates to a method and an electronic pill (20) for administration of at least one drug (3) to a patient, wherein a delivery profile of the at least one drug is determined according to at least one individual parameter of the patient. The at least one individual parameter may particularly relate to a genotype (GEN) or phenotype of the patient and for example comprise a distribution of proteins in the patient's gastrointestinal tract (GIT). Optionally, the individual parameter may be adjusted based on measurements by the electronic pill or external devices during its passage through the patient's gastrointestinal tract.

Abstract: A drug delivery device (50) is provided comprising a drug reservoir (10) and a piston (11). The drug reservoir (10) is provided for comprising a drug and comprises a flexible wall (22) and a dispensing hole (15) for dispensing the drug into an environment of the drug de delivery device (50). The piston (11) is provide for pressing against the flexible wall (22) to compress the drug reservoir (10) for pushing an amount of the drug through the dispensing hole (15). An adhesion interface (51) between a surface of the piston (11) and the flexible wall (22) prevents sliding between the surface of the piston (11) and the flexible wall (22).

Abstract: Disclosed are methods and compositions for amplification of genetic material, including isothermal WGA of single cells.